Quick Answer
Vor Biopharma Inc. reported R&D Expense of $321.53 million for fiscal year 2025.
Vor Biopharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $321.53M | +244.6% |
| 2024 | $93.31M | -1.1% |
| 2023 | $94.31M | +46.1% |
| 2022 | $64.55M | +35.8% |
| 2021 | $47.53M | +50.3% |
| 2020 | $31.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.14M | -35.2% | -94.6% |
| June 30, 2025 | $261.50M | +1098.3% | +879.4% |
| March 31, 2025 | $26.70M | +9.8% | +22.4% |
| September 30, 2024 | $21.82M | -21.0% | -0.0% |
| June 30, 2024 | $21.82M | -8.7% | -10.3% |
| March 31, 2024 | $24.32M | +11.0% | -11.9% |
| September 30, 2023 | $27.61M | +63.6% | +15.5% |
| June 30, 2023 | $23.90M | +55.9% | +9.0% |
- Vor Biopharma Inc. showed an increase of +244.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Vor Biopharma Inc.’s r&d expense has grown by 916.9% (from $31.62 million to $321.53 million).
- The most recent figure is from Vor Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: